PE guideline revised for the first time in 9 years
By Lee, Hye-Kyung | translator Byun Kyung A
21.03.15 10:53:47
가나다라
0
Discount rate lowered, analysis perspective changed and financial impact removed
HIRA newly sets effect projection methodology and supplementary screening drug
The pharmacoeconomic evaluation (PE) guideline revised by South Korea’s Health Insurance Review and Assessment Service (HIRA) for the first time in nine years has been in effect from last January.
The amended 2021 version of the PE guideline reflects the latest evaluation methodology, and specifies the detailed evaluation criteria based on the accumulated experiences and environment of South Korea.
On last Jan. 20, HIRA (President Kim Sun-min) official announced the PE guideline was revised republished.
The PE guideline explains of the criteria for PE on better effective new drug, which was first introduced by the health authority in 2006 for the positive listing system, a
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)